{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Une association \u00e0 doses fixes d\u2019inhibiteurs de points de contr\u00f4le conserve son avantage pour la SSP et la SG \u00e0 5 ans - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"rs07Lk32x0\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2026\/06\/22\/2468-melanome\/\">Une association \u00e0 doses fixes d\u2019inhibiteurs de points de contr\u00f4le conserve son avantage pour la SSP et la SG \u00e0 5 ans<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2026\/06\/22\/2468-melanome\/embed\/#?secret=rs07Lk32x0\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Une association \u00e0 doses fixes d\u2019inhibiteurs de points de contr\u00f4le conserve son avantage pour la SSP et la SG \u00e0 5 ans\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"rs07Lk32x0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2026\/06\/mxcr-2468_diapo1.jpg","thumbnail_width":1280,"thumbnail_height":960,"description":"Chicago \u2013 Une analyse r\u00e9cente des donn\u00e9es \u00e0 5 ans d\u2019une \u00e9tude mondiale sur le m\u00e9lanome r\u00e9v\u00e8le que l\u2019association de doses fixes de nivolumab et de relatlimab conserve son avantage num\u00e9rique sur le nivolumab utilis\u00e9 seul pour ce qui est de la survie globale (SG). La survie sans progression (SSP) obtenue avec cette association \u00e9tait d\u00e9j\u00e0 significativement plus longue 12 mois apr\u00e8s la r\u00e9partition al\u00e9atoire. Or \u00e0 5 ans, elle reste consid\u00e9rablement plus \u00e9lev\u00e9e, m\u00eame si les traitements subs\u00e9quents sont pris en compte. Quant \u00e0 l\u2019innocuit\u00e9 et \u00e0 la tol\u00e9rabilit\u00e9, les taux d\u2019abandons ou d\u2019effets ind\u00e9sirables de grade 3 ou plus sont \u00e0 peine plus \u00e9lev\u00e9s que ceux observ\u00e9s avec le nivolumab en monoth\u00e9rapie"}